Eastman Kodak (Rochester, NY) has promoted Michael L. Marsh to general manager of digital output in the company's health imaging group. Marsh will replace John Farrell, who will become worldwide GM for growth services, a new role in health imaging's
Eastman Kodak (Rochester, NY) has promoted Michael L. Marsh to general manager of digital output in the company's health imaging group. Marsh will replace John Farrell, who will become worldwide GM for growth services, a new role in health imaging's global services organization. Holly Ferrell was appointed earlier as chief marketing officer and divisional vice president of health imaging.
Marsh will be responsible for the development and manufacturing of health imaging's market-leading DryView laser imagers. He is currently GM of the capture business within the company's commercial imaging group, responsible for the design, manufacture, and marketing of high-speed document scanners.
Ferrell directs worldwide product and service marketing strategies, working closely with health imaging's strategic product groups and regional organizations. She oversees product marketing, market research, training and education, and global communications.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.